Chronic cavitary pulmonary histoplasmosis*

Histoplasmose pulmonar cavitària crônica

José Wellington Alves dos Santos, Gustavo Trindade Michel, Mônica Lazzarotto, Juliana Kaczmareck Figaro, Daniel Spilmann, Gustavo Köhler Homrich

Abstract
Histoplasmosis is a systemic mycosis caused by the thermally dimorphic fungus *Histoplasma capsulatum*, which can be isolated from soil contaminated with droppings from birds or bats. Chronic cavitary pulmonary histoplasmosis is one of the rarest clinical presentations of this disease. The differential diagnosis with tuberculosis should be made in patients presenting with cavitated lesions in upper lung segments. We report the case of a female patient with chronic cavitary pulmonary histoplasmosis who had presented with progressive dyspnea and worsening of the radiological pattern over a four-year period.

Keywords: Histoplasmosis; Cavitation; Pulmonary emphysema.

Case report
A 69-year-old female smoker (30 pack-years) homemaker from São Sepe, Brazil, presented with rheumatoid arthritis for 14 years. The patient had undergone a thyroidectomy 20 years before. The epidemiological history was not clear regarding possible fungal exposure. The patient had been experiencing progressive dyspnea, productive cough, recurrent respiratory infections, loss of appetite, nausea and weight loss for 4 years. The patient was using levothyroxine, calcitriol and prednisone 15 mg/day; however, she had previously used methotrexate.

Physical examination revealed that the patient had lost weight (patient weight at the time was 30 kg, and body mass index was 14 kg/m²). No cervical lymph node enlargement, supraclavic-
ular lymph node enlargement or digital clubbing was observed. Pulmonary auscultation revealed only a diffuse reduction in breath sounds. A chest X-ray taken at the onset of the condition (4 years before) showed lung hyperinflation and severely decreased vascular markings in the upper halves of both lung fields (Figure 1). An HRCT scan had revealed paraseptal emphysema, cavities and destruction of the lung parenchyma, predominantly in the upper lobes (Figure 2). Arterial blood gas analysis and the tuberculin skin test revealed no abnormalities. Spirometry showed incipient obstructive lung disease, and treatment with formoterol was initiated. In the previous year, due to worsening of the symptoms, the patient had been submitted to another HRCT scan, which revealed worsening of the radiological pattern (Figure 3). Direct sputum smear microscopy was negative for AFB. The Grocott-Gomori methenamine-silver stain technique revealed intracellular yeast-like structures. Sputum culture and bronchoalveolar lavage fluid culture on Sabouraud dextrose agar revealed the presence of *Histoplasma capsulatum*. Treatment with 200 mg/day of itraconazole was initiated. The patient is currently under outpatient follow-up treatment. The symptoms have improved, and the patient has gained weight.

**Discussion**

Histoplasmosis is a systemic mycosis caused by the thermally dimorphic fungus *H. capsulatum*, which is found in its filamentous form as macroconidia (8–15 µm) or microconidia (2–4 µm) in the soil of endemic areas, such as the USA, Latin America, Southeast Asia and Africa. In human tissue, *H. capsulatum* converts into oval, single-budding yeasts of 2–4 µm. Infection generally occurs through the inhalation of airborne microconidia during work or recreational activities that bring the participants into contact with soil contaminated with bat or bird feces (in old buildings, bridges or caves). In Brazil, *H. capsulatum* can be found in various states, such as Rio Grande do Sul, Rio de Janeiro, São Paulo, Minas Gerais and Mato Grosso. The clinical spectrum of the disease ranges from acute pulmonary infection to chronic pulmonary infection and includes disseminated histoplasmosis. The disseminated form of the disease affects principally immunocompromised patients. Acute symptomatic *H. capsulatum* infection is observed in less than 1% of infected patients, most patients either being asymptomatic or presenting mild symptoms that are later found to be unrelated to histoplasmosis. In addition, the disease usually has a self-limiting course. These factors contribute to the underdiagnosis of histoplasmosis, which can lead to the initiation of empirical treatment for tuberculosis.

Affecting the upper lobes of the lungs and accompanied by fibrosis, CCPH is related to continuous exposure to the agent and is the only fungal infection that seems to affect primarily patients of advanced age. This might be...
Chronic cavitary pulmonary histoplasmosis


1163

...estimated rate of empirical treatment for tuberculosis is high (50%), which delays the detection and treatment of CCPH. In addition to tuberculosis, the differential diagnosis should include nontuberculous mycobacterial infections, sarcoidosis, coccidioidomycosis, aspergillosis, paracoccidioidomycosis and carcinoma.

Diagnosis can be established through the isolation of the fungus from sputum or from samples obtained through bronchoscopy in 60-85% of the cases when multiple samples are obtained. These samples should be stained using the Grocott-Gomori methenamine-silver stain technique. Culture on Sabouraud dextrose agar is the gold standard for the etiologic diagnosis, although the result might not be known for 2-4 weeks. The immunodiffusion test is appropriate to screen patients, and the sensitivity of the test is approximately 100%; the relevance of the test is greater in areas in which the prevalence of the fungus is low. Histoplasmin skin test can yield false-negative results in patients with CCPH and therefore is inappropriate as a screening test. The use of the urinary antigen test has been limited because the antigen can be detected in only 10-20% of CCPH patients.

The treatment of choice for CCPH is itraconazole, at a dose of 400-600 mg/day, for 1-2 years. In severe cases requiring hospitalization, amphotericin B can be used. However, it is important to be on the alert for possible recurrence, which can occur in 9-15% of the cases regardless of which of the two antifungal agents are used.

A rare manifestation of histoplasmosis, CCPH should be included in the differential diagnosis of tuberculosis in patients with cavitated lesions in the upper segments of the lungs. Therefore, screening for fungi during sputum examination using the Grocott-Gomori methenamine-silver stain technique and culture of samples on appropriate culture media, as well as the immunodiffusion test, should be incorporated into the routine diagnostic investigation.

References


Due to a close association between pulmonary emphysema and the development of this form of the disease, The disease primarily affects White males who have had the acute form of the disease and are exposed to the agent. The manifestation of CCPH in females is rare. Systemic manifestations are nonspecific and include fatigue, fever, night sweats, anorexia and weight loss. Pulmonary symptoms include productive cough and dyspnea, a profile similar to that of COPD. When left untreated, CCPH is accompanied by progressive respiratory failure due to lung volume loss, and the five-year survival rate can be as low as 50%. The radiological aspect of the initial lesion is characterized by foci of interstitial inflammatory infiltrate, adjacent to emphysematous bullae, and the lesion commonly affects the apical and apicoposterior segments of the upper lobes. Thickening of the walls of the bullae is common and is followed by necrosis and increased fibrosis, which leads to lung volume loss. This continuous process culminates with large and persistent cavities that can affect an entire lobe. The dissemination of fungal material to the hanging portions of the lungs might be the mechanism of development of interstitial fibrosis in the lower lobes through the creation of new inflammatory foci. Mediastinal adenopathy is not observed in this clinical form, which distinguishes CCPH from other granulomatous diseases, such as sarcoidosis.

Similar to post-primary tuberculosis, CCPH can present with malaise, cough and night sweats; these, however, are milder in CCPH. Due to the rate of incidence of tuberculosis in Brazil (43.78/100,000 population in 2005), the estimated rate of empirical treatment for tuberculosis is high (50%), which delays the detection and treatment of CCPH. In addition to tuberculosis, the differential diagnosis should include nontuberculous mycobacterial infections, sarcoidosis, coccidioidomycosis, aspergillosis, paracoccidioidomycosis and carcinoma.

Diagnosis can be established through the isolation of the fungus from sputum or from samples obtained through bronchoscopy in 60-85% of the cases when multiple samples are obtained. These samples should be stained using the Grocott-Gomori methenamine-silver stain technique. Culture on Sabouraud dextrose agar is the gold standard for the etiologic diagnosis, although the result might not be known for 2-4 weeks. The immunodiffusion test is appropriate to screen patients, and the sensitivity of the test is approximately 100%; the relevance of the test is greater in areas in which the prevalence of the fungus is low. Histoplasmin skin test can yield false-negative results in patients with CCPH and therefore is inappropriate as a screening test. The use of the urinary antigen test has been limited because the antigen can be detected in only 10-20% of CCPH patients.

The treatment of choice for CCPH is itraconazole, at a dose of 400-600 mg/day, for 1-2 years. In severe cases requiring hospitalization, amphotericin B can be used. However, it is important to be on the alert for possible recurrence, which can occur in 9-15% of the cases regardless of which of the two antifungal agents are used.

A rare manifestation of histoplasmosis, CCPH should be included in the differential diagnosis of tuberculosis in patients with cavitated lesions in the upper segments of the lungs. Therefore, screening for fungi during sputum examination using the Grocott-Gomori methenamine-silver stain technique and culture of samples on appropriate culture media, as well as the immunodiffusion test, should be incorporated into the routine diagnostic investigation.

References


About the authors

José Wellington Alves dos Santos
Director of the Department of Pulmonology. Santa Maria University Hospital, Federal University of Santa Maria, Santa Maria, Brazil.

Gustavo Trindade Michel
Adjunct Professor. Santa Maria University Hospital, Federal University of Santa Maria, Santa Maria, Brazil.

Mônica Lazzarotto
Resident in Pulmonology. Department of Pulmonology, Santa Maria University Hospital, Federal University of Santa Maria, Santa Maria, Brazil.

Juliana Kaczmareck Figaro
Medical Student. Federal University of Santa Maria, Santa Maria, Brazil.

Daniel Spilmann
Medical Student. Federal University of Santa Maria, Santa Maria, Brazil.

Gustavo Köhler Homrich
Medical Student. Federal University of Santa Maria, Santa Maria, Brazil.